Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Direct...
December 14 2017 - 4:30PM
Business Wire
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that
Executive Chairman John Martin, PhD will transition from his
current role of Executive Chairman to Chairman of the Board of
Directors effective March 9, 2018. Dr. Martin was named Executive
Chairman on March 10, 2016, when he was succeeded as CEO by John
Milligan, PhD. Dr. Martin served as CEO of Gilead from 1996 to
2016, having joined the company in 1990 as the Vice President of
Research and Development. During his time as CEO, he built the
company’s portfolio to 24 marketed products with annual revenues of
more than $32 billion.
“John's scientific and business leadership has been notable for
the development of Gilead’s portfolio of HIV and viral hepatitis
medicines and commitment to worldwide access for patients. We are
all grateful that he will continue to help guide the company as
Chairman of the Board,” said Dr. Milligan, President and CEO of
Gilead.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. Gilead’s mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on Twitter
(@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5
or 1-650-574-3000.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171214006171/en/
Gilead Sciences, Inc.Sung Lee, 650-524-7792InvestorsAmy Flood,
650-522-5643Media
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024